Department of (Experimental) Vascular Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands.
Lupus. 2024 Oct;33(12):1373-1378. doi: 10.1177/09612033241274515. Epub 2024 Aug 17.
The gut microbiome is recognized as a factor that could potentially contribute to the persistent antibodies of antiphospholipid syndrome (APS). Gut microbial interventions can both induce and mitigate APS in mice. In human APS patients, anti-beta-2-glycoprotein I (β2GP-1) titers correlate with antibody titers against a gut commensal protein homologous to β2GP-1.
To investigate the effect of the intestinal microenvironment on human APS. Methods We cross-sectionally compared intestinal microbiota composition quantified by shotgun sequencing; fecal short chain fatty acids (SCFAs), bacterial metabolites known to affect autoimmune processes; and fecal calprotectin, an intestinal inflammatory marker, in APS patients and healthy controls.
Neither alpha nor beta diversity of the gut microbiota differed between APS patients (n = 15) and controls (n = 16) and no taxa were differentially abundant. Moreover, fecal SCFAs and fecal calprotectin, did not differ between the groups.
Gut microbiome effects on the APS phenotype are likely not driven by bacterial overabundance, SCFA production or intestinal inflammation.
肠道微生物组被认为是可能导致抗磷脂综合征（APS）持续抗体的因素之一。肠道微生物干预既能在小鼠中诱导又能减轻 APS。在人类 APS 患者中，抗β-2-糖蛋白 I（β2GP-1）滴度与针对与 β2GP-1 同源的肠道共生蛋白的抗体滴度相关。
研究肠道微环境对人类 APS 的影响。方法：我们通过测序技术对肠道微生物群落组成进行了横断面比较；粪便短链脂肪酸（SCFAs），已知影响自身免疫过程的细菌代谢产物；和粪便钙卫蛋白，一种肠道炎症标志物，在 APS 患者和健康对照组中进行了比较。
APS 患者（n = 15）和对照组（n = 16）之间肠道微生物群落的α多样性或β多样性均无差异，且不存在差异丰度的分类群。此外，两组之间粪便 SCFAs 和粪便钙卫蛋白无差异。
肠道微生物组对 APS 表型的影响可能不是由细菌过度生长、SCFA 产生或肠道炎症驱动的。
